197 related articles for article (PubMed ID: 33384014)
1. Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations.
Cheng CM; So TW; Bubp JL
Ann Pharmacother; 2021 Oct; 55(10):1185-1194. PubMed ID: 33384014
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
Pritchard D; Patel JN; Stephens LE; McLeod HL
Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
[TBL] [Abstract][Full Text] [Related]
3. A Web-Based Pharmacogenomics Search Tool for Precision Medicine in Perioperative Care.
Zarei S; Costas Y; Orozco G; Zaydlin M; Mirtar A; Abouali M; Diaz-Marty C; Akhlaghipour G; Fernandez Altamirano P; Gonzalez Cardona AR; Reiley LE; Mirzakhani H
J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32708157
[No Abstract] [Full Text] [Related]
4. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic biomarkers in drug labels: what do they tell us?
Tutton R
Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics: from discovery to patient care.
Shin J; Kayser SR; Langaee TY
Am J Health Syst Pharm; 2009 Apr; 66(7):625-37. PubMed ID: 19299369
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
Schuck RN; Grillo JA
AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
[TBL] [Abstract][Full Text] [Related]
10. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic biomarker information on drug labels of the Spanish Agency of Medicines and Sanitary products: evaluation and comparison with other regulatory agencies.
Estévez-Paredes M; Mata-Martín MC; de Andrés F; LLerena A
Pharmacogenomics J; 2024 Jan; 24(1):2. PubMed ID: 38233388
[TBL] [Abstract][Full Text] [Related]
12. The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality?
Vladutiu GD
Mol Genet Metab; 2008 Jan; 93(1):1-4. PubMed ID: 18054511
[No Abstract] [Full Text] [Related]
13. Design and evaluation of a pharmacogenomics information resource for pharmacists.
Romagnoli KM; Boyce RD; Empey PE; Ning Y; Adams S; Hochheiser H
J Am Med Inform Assoc; 2017 Jul; 24(4):822-831. PubMed ID: 28339805
[TBL] [Abstract][Full Text] [Related]
14. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
15. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
[TBL] [Abstract][Full Text] [Related]
16. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
Vivot A; Boutron I; Ravaud P; Porcher R
Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
[TBL] [Abstract][Full Text] [Related]
17. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts.
Pai SA; Kshirsagar N
J Clin Pharmacol; 2016 Oct; 56(10):1232-42. PubMed ID: 26873003
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic information for patients on drug labels.
Haga SB; Mills R; Moaddeb J
Pharmgenomics Pers Med; 2014; 7():297-305. PubMed ID: 25342916
[TBL] [Abstract][Full Text] [Related]
19. Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
Filipski KK; Pacanowski MA; Ramamoorthy A; Feero WG; Freedman AN
Pharmacogenet Genomics; 2016 Jul; 26(7):334-9. PubMed ID: 27058883
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
Verbelen M; Weale ME; Lewis CM
Pharmacogenomics J; 2017 Oct; 17(5):395-402. PubMed ID: 28607506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
